检索结果-南通市图书馆

Mice-lacking LMP2, immuno-proteasome subunit, as an animal model of spontaneous uterine leiomyosarcoma

Protein & Cell 2010年第8期1卷 711-717页

作者： Takuma Hayashi akiko horiuchi Kenji Sano Nobuyoshi Hiraoka Yae Kanai Tanri Shiozawa Susumu Tonegawa Ikuo Konishi Department of Immunology and Infectious Disease Shinshu University Graduate School of MedicineMatsumotoNagano 390-8621Japan Department of Obstetrics and Gynecology Shinshu University School of MedicineMatsumotoNagano 390-8621Japan Department of Laboratory Medicine Shinshu University HospitalMatsumotoNagano 390-8621Japan Pathology Division National Cancer Center Research InstituteTokyo 104-0045Japan Picower Institution and Department of Biology Massachusetts Institute of TechnologyCambridgeMassachusetts 02139USA Department of Obstetrics and Gynecology Kyoto University Graduate School of MedicineSakyo-kuKyoto 606-8501Japan Promoting Business using Advanced Technology Japan Science and Technology Agency(JST)Kawaguchi-shiSaitama 332-0012Japan

Uterine tumors are the most common type of gynecologic *** leiomyosarcoma(LMS)is rare,accounting for 2%to 5%of tumors of the uterine *** LMS develops more often in the muscle tissue layer of the uterine body than in the uterine *** development of gynecologic tumors is often correlated with female hormone secretion;however,the development of uterine LMS is not substantially correlated with hormonal conditions,and the risk factors are not yet *** evaluation combined with PET/CT can be useless in the diagnosis and surveillance of uterine ***,a diagnostic biomarker,which distinguishes malignant LMS and benign tumor leiomyoma(LMA)is yet to be ***,it is necessary to analyze risk factors associated with uterine LMS in order to establish a method of ***2-deficient mice spontaneously develop uterine LMS,with a disease prevalence of~40%by 14 months of *** is therefore of interest whether human uterine LMS shows a loss of LMP2 *** found LMP2 expression is absent in human LMS,but present in human ***,defective LMP2 expression may be one of the risk factors for ***2 is potentially a diagnostic biomarker for uterine LMS,and gene therapy with LMP2-encording DNA may be a new therapeutic approach.

关键词： LMP2 uterine leiomyosarcoma uterine leiomyoma diagnostic biomarker

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Candidate Molecules and ki-67/MIB1 as Novel Diagnostic Biomarker for Human Uterine Mesenchymal Tumors

引用

International Journal of Medical Physics, Clinical Engineering and Radiation Oncology 2013年第3期2卷 1-6页

作者： Takuma Hayashi akiko horiuchi Nobuo Yaegashi Susumu Tonegawa Ikuo Konishi Department of Immunology and Infectious Disease Shinshu University School of MedicineMatsumoto Nagano Japan Department of Obstetrics and Gynecology Kyoto University Graduate School of MedicineKyoto-city Kyoto Japan Department of Obstetrics and Gynecology Kyoto University Graduate School of Medicine Kyoto-city Kyoto Japan Department of Obstetrics and Gynecology Tohoku University Graduate School of Medicine Miyagi Japan horiuchi Ladies Clinic Matsumoto Nagano 390-0821 Japan Picower Institution and Department of Biology Massachusetts Institute of TechnologyCambridge MA 02139-4307 USA

Human uterine leiomyosarcoma (LMS) develops more often in the muscle tissue layer of the uterine body than in the uterine cervix. The development of gynecologic tumors is often correlated with female hormone secretion;however, the development of uterine LMS is not substantially correlated with hormonal conditions, and the risk factors are not yet known. Importantly, a diagnostic-biomarker, which distinguishes malignant uterine LMS from benign tumor leiomyoma (LMA), is yet to be established. Accordingly, it is necessary to analyze risk factors associated with uterine LMS, to establish a clinical treatment method. Protea some β-ring subunit LMP2/β1i-deficient mice spontaneously develop uterine LMS, with a disease prevalence of ~40% by 14 months of age. We found LMP2/β1i expression to be absent in human uterine LMS, but present in human LMA. Therefore, defective-LMP2/β1i expression may be one of the risk factors for human uterine LMS. LMP2/β1i is a potential diagnostic-biomarker under the combination of candidate molecules, for instance cyclin B1, cyclin E and calponin h1 and ki-67/MIB1 counts for uterine mesenchymal tumors, especially human uterine LMS, and may be a targeted-molecule for a new therapeutic approach.

关键词： LMP2/β1i Uterine Leiomyosarcoma Uterine Leiomyoma Biomarker

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：